{
  "citations" : [ {
    "@id" : "https://pharmgkb.org/literature/7283333",
    "@context" : "https://api.pharmgkb.org/jsonld/literature.jsonld",
    "id" : 7283333,
    "resourceId" : "21412232",
    "title" : "Pharmacogenetics: from bench to byte--an update of guidelines.",
    "_sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
    "authors" : [ "Swen J J", "Nijenhuis M", "de Boer A", "Grandia L", "Maitland-van der Zee A H", "Mulder H", "Rongen G A P J M", "van Schaik R H N", "Schalekamp T", "Touw D J", "van der Weide J", "Wilffert B", "Deneer V H M", "Guchelaar H-J" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ "Animals", "Aryl Hydrocarbon Hydroxylases", "Cytochrome P-450 CYP2C9", "Drug Administration Schedule", "Drug-Related Side Effects and Adverse Reactions", "Humans", "Pharmaceutical Preparations", "Pharmacogenetics", "Practice Guidelines as Topic" ],
    "month" : 5,
    "nonHuman" : false,
    "objCls" : "Literature",
    "page" : "662-73",
    "pgkbPublication" : false,
    "pubDate" : "2011-05-01T00:00:00-07:00",
    "summary" : "Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).",
    "type" : "Article",
    "version" : 2,
    "volume" : "89",
    "xrefs" : [ {"@id":"https://pharmgkb.org/crossReference/pubMed/21412232","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":769250885,"resource":"PubMed","resourceId":"21412232","_url":"https://www.ncbi.nlm.nih.gov/pubmed/21412232"}, {"@id":"https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449247827,"resource":"DOI","resourceId":"10.1038/clpt.2011.34","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.34"} ],
    "year" : 2011
  } ],
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166104951",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166104951",
    "name" : "Annotation of DPWG Guideline for irinotecan and UGT1A1",
    "cancerGenome" : false,
    "descriptiveVideoId" : "",
    "guidelineGenes" : [ ],
    "history" : [ {
      "id" : 1183704491,
      "date" : "2011-08-10T00:00:00-07:00",
      "type" : "Create",
      "version" : 0
    }, {
      "id" : 1450414915,
      "date" : "2019-05-23T06:43:59.845-07:00",
      "description" : "Annotation current with November 2018 DPWG Guideline release",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1450820671,
      "date" : "2019-10-03T15:43:15.918-07:00",
      "description" : "No changes based on August 2019 guideline",
      "type" : "Note",
      "version" : 0
    }, {
      "id" : 1450956385,
      "date" : "2020-01-31T13:36:54.782-08:00",
      "description" : "Updated link to 2011 DPWG methods",
      "type" : "Update",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/7283333","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":7283333,"resourceId":"21412232","title":"Pharmacogenetics: from bench to byte--an update of guidelines.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21412232","objCls":"Literature","type":"Article","xrefs":[{"@id":"https://pharmgkb.org/crossReference/pubMed/21412232","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":769250885,"resource":"PubMed","resourceId":"21412232","_url":"https://www.ncbi.nlm.nih.gov/pubmed/21412232"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449247827,"resource":"DOI","resourceId":"10.1038/clpt.2011.34","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.34"}]}, {"@id":"https://pharmgkb.org/literature/15103288","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15103288,"resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","objCls":"Literature","type":"Web Page","xrefs":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450815695,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"}]}, {"@id":"https://pharmgkb.org/literature/15102465","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15102465,"resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","objCls":"Literature","type":"Web Page","xrefs":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450415575,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"}]} ],
    "recommendation" : true,
    "relatedAlleles" : [ ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA450085",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA450085",
      "name" : "irinotecan",
      "version" : 15
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA420",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA420",
      "symbol" : "UGT1A1",
      "name" : "UDP glucuronosyltransferase 1 family, polypeptide A1",
      "version" : 6109
    } ],
    "source" : "Dutch Pharmacogenetics Working Group",
    "summaryMarkdown" : {
      "id" : 1447981882,
      "html" : "<p>Dose reductions are recommended for irinotecan for patients who are UGT1A1 *28/*28 or UGT1A1 PM, starting with 70% of starting dose and increasing as tolerated, guided by neutrophil count.</p>\n",
      "version" : 1
    },
    "summaryVideoId" : "",
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1447981881,
      "html" : "<h3 id=\"november-2018-update\">November 2018 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for irinotecan based on UGT1A1 genotype.  They recommend reducing the initial dose for patients who are poor metabolizers or homozygotes for UGT1A1*28.</p>\n<p><em>Wording in table taken from the <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf\" target=\"_blank\">Dutch guidelines</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>\n</thead>\n<tbody>\n<tr><td>UGT1A1 *1/*28</td><td>irinotecan</td><td>This genetic variation (*1/*28) is more common in Western populations than the wild-type (*1/*1). This means that treatment is largely geared to patients with this genetic variation. Adjustment of the treatment is therefore not useful.</td><td>NO action is needed for this gene-drug interaction</td></tr>\n<tr><td>UGT1A1 *28/*28</td><td>irinotecan</td><td>Serious, life-threatening adverse events occur more often in patients with this genetic variation. The genetic variation reduces conversion of irinotecan to inactive metabolites.</td><td>Start with 70% of the standard dose If the patient tolerates this initial dose, the dose can be increased, guided by the neutrophil count.</td></tr>\n<tr><td>UGT1A1 IM</td><td>irinotecan</td><td>This genetic variation (IM) is more common in Western populations than the wild-type (*1/*1). This means that treatment is largely geared to patients with this genetic variation. Adjustment of the treatment is therefore not useful.</td><td>NO action is needed for this gene-drug interaction.</td></tr>\n<tr><td>UGT1A1 PM</td><td>irinotecan</td><td>Serious, life-threatening adverse events occur more often in patients with this genetic variation. The genetic variation reduces conversion of irinotecan to inactive metabolites.</td><td>Start with 70% of the standard dose If the patient tolerates this initial dose, the dose can be increased, guided by the neutrophil count.</td></tr>\n</tbody>\n</table>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0001693.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Read about gene information from DPWG</a></p>\n<h3 id=\"2011-guideline\">2011 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for irinotecan based on UGT1A1 genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They recommend reducing the dose for *28 homozygous patients receiving more than 250 mg/m<sup>2</sup>.</p>\n<table class=\"table\">\n<thead>\n<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>\n</thead>\n<tbody>\n<tr><td>*1/*28</td><td>None.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints..</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression.</td></tr>\n<tr><td>*28/*28</td><td>Dose &gt;250mg/m<sup>2</sup>: reduce initial dose by 30%. Increase dose in response to neutrophil count.  Dose &lt;=250mg/m<sup>2</sup>: no dose adjustment.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia &lt; 0.5x10<sup>9</sup>/l; leucopenia &lt; 1.0x10<sup>9</sup>/l; thrombocytopenia &lt; 25x10<sup>9</sup>/l; life-threatening complications from diarrhea.</td></tr>\n</tbody>\n</table>\n<ul>\n<li>*See <a href=\"http://www.pharmgkb.org/page/dpwg\">Methods </a> or [Article:<a href=\"/pmid/18253145\">18253145</a>] for definition of &quot;moderate&quot; quality.</li>\n</ul>\n",
      "version" : 12
    },
    "userId" : "alie",
    "version" : 20,
    "xrefs" : [ ]
  }
}